The Technology
Fibrosis is the abnormal accumulation of fibrous extracellular matrix, causing a group of conditions known as fibrotic diseases, such as cystic fibrosis, systemic sclerosis and scleroderma. Fibrosis can be a primary condition or a secondary response, as well as promote primary tumor growth and metastatic spread. The gradual progression of fibrotic diseases leads to organ malfunction, associated with approximately 45% of mortality cases in the western world. The current standard of care (SoC) targets inflammation reduction (using steroids and TGFβ inhibitors), causing multiple adverse side effects.The technology targets core fibrotic proteins, inhibiting and controlling fibrillogenesis and facilitating fibrosis inhibition. This technology is validated in-vitro.
Advantages
- Novel mode of action, targeting primary factors of fibrosis (in contrast to current SoC), thus poses higher efficacy and lower side effects.
- Potentially inhibits all fibrotic diseases as it affects core fibrotic machinery
- Easier target engagement – located in the extracellular space.
- Inhibiting later and additional stages of the fibrotic process
Applications and Opportunities
Therapeutic agent for fibrosis, including:
- Systemic diseases
- Cancer
- Post-operation
- Cardiomyopathies
- cosmetics
Business Development Contacts